Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.46 |
| ▸ | GRM5 | P41594 | 8/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.43 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436177 | 0.86 | PDK4 (0.52) | PDK4GRM1GRM5HTR6EED | |
| SCHEMBL22957463 | 0.86 | PDK4 (0.51) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL19212418 | 0.84 | TRPV1 (0.40) | CDK9CCNT1JAK1 | |
| SCHEMBL17825458 | 0.84 | GPR119 (0.55) | PDK4GRM1GRM5HTR6GPR119 | |
| SCHEMBL25377179 | 0.84 | PDK4 (0.52) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL13993111 | 0.83 | GRM1 (0.57) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL22325010 | 0.83 | PDK4 (0.48) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL29580725 | 0.83 | PDK4 (0.48) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL31342062 | 0.82 | PDK4 (0.50) | PDK4GRM1GRM5HTR6CDK9 | |
| SCHEMBL24310174 | 0.82 | PDK4 (0.55) | PDK4GRM1GRM5HTR6CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PDK4 3136/4885GRM1 1928/4885GRM5 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.